Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 16;103:5243. doi: 10.2340/actadv.v103.5243

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Acta Dermato-Venereologica

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License

PMC Copyright notice

Fig 2 — Primary effectiveness outcomes (mean, 95% confidence interval (95% CI)) of 16 weeks’ treatment with upadacitinib. (A) Outcomes of the total cohort. (B) Outcomes stratified by ^adup-R/naïve and ^bdup-NR. (C) Outcomes stratified by ^abari-R/naïve and ^bbari-NR. dup-R/naïve: dupilumab responders/naïve patients; dup-NR: dupilumab non-responders; bari-R/naïve: baricitinib responders/naïve patients; bari-NR: baricitinib non-responders; EASI: Eczema Area and Severity Index; NRS: numerical rating scale; DLQI: Dermatology Life Quality Index; POEM: Patient-Oriented Eczema Measure; ns: non-significant. ***p<0.001, bars represent 95% CI.